Download PDF
Thromb Haemost 1978; 39(03): 675-682
DOI: 10.1055/s-0038-1646742
Original Article
Schattauer GmbH Stuttgart

Treatment of Congenital Factor VII Deficiency with a New Concentrate

G Mariani
1   The Department of Hematology, University of Rome, Italy
,
P M Mannucci
2   The Hemophilia & Thrombosis Centre Angelo Bianchi Bonomi University of Milan, Italy
,
M G Mazzucconi
1   The Department of Hematology, University of Rome, Italy
,
A Capitanio
2   The Hemophilia & Thrombosis Centre Angelo Bianchi Bonomi University of Milan, Italy
› Author Affiliations
Further Information

Publication History

Received 02 August 1977

Accepted 24 December 1977

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A new factor VII concentrate, made from ACD plasma by a process involving successive absorptions of cryoprecipitate supernatant on DEAE Sephadex and of the resulting supernatant on Al(OH)3, was administered to 10 patients with severe factor VII deficiency. 5 patients received only one dose for treatment of a single bleeding episode, the remaining 5 were given multiple infusions (47) for spontaneous hemorrhages or for the prevention of surgical bleeding. In vivo factor VII recovery ranged from 43 to 126% (average 88%) of the assayed in vitro activity of the concentrate. A dose of 0.5 u/kg was found to produce a 1% rise of the plasma factor VII levels. The mean half-life on injected factor VII as assessed in 7 kinetic studies was 205 min (range 168-234). Spontaneous bleeding was easily controlled by the concentrate and major surgical procedures (two tonsillectomies) could be performed without complications. 1 patient developed HBsAg positive hepatitis, but otherwise no serious side effects were observed. Factor VII concentrate reduces the risk of precipitating circulatory overload associated with the use of plasma and avoids the unnecessary rise of factor II, IX and X which follows prothrombin complex concentrates.

 

  • References

  • 1 Aledort LM. 1977; Factor IX and thrombosis. Scandinavian Journal of Haematology Suppl 30: 40
    PubMedSearch in Google Scholar
  • 2 Bidwell E, Booth JM, Dike GWR, Denson KWE. 1967; The preparation for therapeutic use of a concentrate of factor IX containing also factors II, VII and X. British Journal of Haematology 13: 568
    CrossrefPubMedSearch in Google Scholar
  • 3 Biggs R, Denson KWE. 1963; The fate of prothrombin and factors VII, IX and X transfused to patients deficient in these factors. British Journal of Haematology 9: 532
    CrossrefPubMedSearch in Google Scholar
  • 4 Brecher G, Cronkite EP. 1950; Morphology and enumeration of human blood platelets. Journal of Applied Physiology 3: 365
    CrossrefPubMedSearch in Google Scholar
  • 5 Bruning PF, Loeliger EA. 1971; Prothrombal a new concentrate of human prothrombin complex for clinical use. British Journal of Haematology 21: 377
    CrossrefPubMedSearch in Google Scholar
  • 6 Denson KWE. 1972. In: Biggs R. (ed.) Human blood Coagulation, Haemostasis and Thrombosis. Blackwell Scientific Publications; Oxford: 587
  • 7 Gilchrist GC, Ekert H, Shanbrom E, Hammond D. 1969; Evaluation of a new concentrate for the treatment of factor IX deficiency. New England Journal of Medicine 280: 291
    CrossrefPubMedSearch in Google Scholar
  • 8 Hawiger D, Niewiarowski S, Gurevich V, Thomas PP. 1970; Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. Journal of Laboratory and Clinical Medicine 75: 93
    PubMedSearch in Google Scholar
  • 9 Hitzig WH, Zollinger W. 1958; Kongenitaler Faktor VII-Mangel. Familienuntersuchung und physiologische Studien über den Faktor VII. Helvetica paediatrica acta 13: 189
    PubMedSearch in Google Scholar
  • 10 Hoag MJ, Aggeler PM, Forrell AH. 1960; Disappearance rate of concentrated proconvertin extracts in congenital and acquired hypoproconvertivemia. Journal of Clinical Investigation 39: 554 1960
    CrossrefPubMedSearch in Google Scholar
  • 11 Hoag MS, Johnson FJ, Robinson JA, Aggeler PM. 1969; Treatment of hemophilia B with a new clotting-factor concentrate. New England Journal of Medicine 280: 581
    CrossrefPubMedSearch in Google Scholar
  • 12 Ingram GIC. 1965; Blood coagulation factor VIII. genetics, physiological control, and bioassay. Advances in Clinical Chemistry 8: 189
    PubMedSearch in Google Scholar
  • 13 Josso F, Prou-Wartelle O, Menaché D. 1964; Durée de vie de la proconvertine (factor VII). Nouvelle Revue Française d’Hématologie 4: 572
    PubMedSearch in Google Scholar
  • 14 Mannucci PM, Pareti FI. 1974; Platelet functions after intravenous administration in man of cyclic-AMP and related drugs. Journal of Laboratory and Clinical Medicine 84: 828
    PubMedSearch in Google Scholar
  • 15 Marder VJ, Shulman NR. 1964; Clinical aspects of congenital factor VII deficiency. American Journal of Medicine 37: 182
    CrossrefPubMedSearch in Google Scholar
  • 16 Nilsson IM, Alhberg A, Bjorlin G. 1971; Clinical experience with a Swedish factor IX concentrate. Acta Medica Scandinavica 190: 257
    PubMedSearch in Google Scholar
  • 17 Soulier JP, Blatrix Ch, Steinbuch M. 1964; Fractions coagulants contenant les facteurs de coagulation adsorbable par le phosphate tricalcique. Presse Médicale 72: 1223
    PubMedSearch in Google Scholar
  • 18 Tullis JL, Melin M, Jurgian P. 1965; Clinical use of human prothrombin complexes. New England Journal of Medicine 273: 667
    CrossrefPubMedSearch in Google Scholar
  • 19 Vermylen C, De Vreker RA, Verstraete M. 1963; A rapid enzymatic method for assay of fibrinogen; fibrin polymerization time (FPT-test). Clinica chimica acta 8: 418
    CrossrefPubMedSearch in Google Scholar
  • 20 Wilson WJ, Ingram GIC, Hills M. 1971; The use of kaolin or contact product in the one-stage assay of factor VII. Coagulation 4: 113
    PubMedSearch in Google Scholar